BioXcel Therapeutics Inc (OQ:BTAI)

Mar 19, 2020 07:15 am ET
BioXcel Therapeutics Provides an Update on its Ongoing Phase 3 SERENITY Trials
BioXcel Therapeutics, Inc. (“BTI” or “Company”) (Nasdaq: BTAI), a clinical-stage biopharmaceutical company utilizing artificial intelligence to identify improved therapies in neuroscience and immuno-oncology, today announced that more than...
Mar 09, 2020 07:00 am ET
BioXcel Therapeutics Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Business Update
BioXcel Therapeutics, Inc. (“BTI” or “Company”) (Nasdaq: BTAI), a clinical-stage biopharmaceutical company utilizing artificial intelligence to identify improved therapies in neuroscience and immuno-oncology, today announced its quarterly results...
Mar 02, 2020 07:00 am ET
BioXcel Therapeutics to Host Fourth Quarter and Full Year 2019 Operating and Financial Results Conference Call and Webcast
BioXcel Therapeutics, Inc. (“BTI” or “Company”) (Nasdaq: BTAI), a clinical-stage biopharmaceutical company utilizing artificial intelligence to identify improved therapies in neuroscience and immuno-oncology, today announced it will host a...
Feb 26, 2020 07:00 am ET
BioXcel Therapeutics to Present at Two Upcoming Healthcare Investor Conferences
BioXcel Therapeutics, Inc. (“BTI” or “Company”) (Nasdaq: BTAI), a clinical-stage biopharmaceutical company utilizing artificial intelligence to identify improved therapies in neuroscience and immuno-oncology, today announced that Dr. Vimal Mehta,...
Feb 20, 2020 07:30 am ET
BioXcel Therapeutics Announces Pricing of Public Offering of Common Stock
BioXcel Therapeutics, Inc. (“BTI” or the “Company”) (Nasdaq: BTAI), a clinical-stage biopharmaceutical development company, today announced the pricing of an underwritten public offering of 2,000,000 shares of common stock at a public offering...
Feb 19, 2020 04:54 pm ET
BioXcel Therapeutics Announces Proposed Public Offering of Common Stock
BioXcel Therapeutics, Inc. (“BTI” or the “Company”) (Nasdaq: BTAI), a clinical-stage biopharmaceutical development company, today announced that it has commenced an underwritten public offering of 2,000,000 shares of its common stock. In connection...
Feb 18, 2020 07:00 am ET
BioXcel Therapeutics Announces Initiation of a Phase 2 Study Designed to Assess Agitation-Associated Biomarkers and their Response to BXCL501
BioXcel Therapeutics, Inc. (“BTI” or “Company”) (Nasdaq: BTAI), a clinical-stage biopharmaceutical company utilizing artificial intelligence approaches to identify and advance the next wave of medicines in neuroscience and immuno-oncology, today...
Feb 07, 2020 07:00 am ET
BioXcel Therapeutics to Present at the 2020 BIO CEO & Investor Conference
BioXcel Therapeutics, Inc. (“BTI” or “Company”) (Nasdaq: BTAI), a clinical-stage biopharmaceutical company utilizing artificial intelligence approaches to identify and advance the next wave of medicines in neuroscience and immuno-oncology, today...
Feb 05, 2020 07:00 am ET
BioXcel Therapeutics Announces FDA Clearance of IND Application for BXCL501 for the Treatment of Opioid Withdrawal Symptoms
BioXcel Therapeutics, Inc. (“BTI” or “Company”) (Nasdaq: BTAI), a clinical-stage biopharmaceutical company utilizing artificial intelligence approaches to identify and advance the next wave of medicines in neuroscience and immuno-oncology, today...
Jan 07, 2020 07:00 am ET
BioXcel Therapeutics Announces First Patient Enrolled in Phase 1b/2 Study of BXCL501 for Acute Treatment of Agitation Associated with Dementia
BioXcel Therapeutics (“BTI” or “Company”) (Nasdaq: BTAI), a clinical-stage biopharmaceutical company utilizing artificial intelligence approaches to identify and advance the next wave of medicines in neuroscience and immuno-oncology, today...
Dec 30, 2019 07:00 am ET
BioXcel Therapeutics Announces Initiation of Pivotal Phase 3 Studies of BXCL501 for Acute Treatment of Agitation in Patients with Schizophrenia and Bipolar Disorder
BioXcel Therapeutics (“BTI” or “Company”) (Nasdaq: BTAI), a clinical-stage biopharmaceutical company utilizing artificial intelligence approaches to identify and advance the next wave of medicines in neuroscience and immuno-oncology, today...
Dec 11, 2019 07:00 am ET
BioXcel Therapeutics to Expand Study of BXCL701 into Multiple Advanced Solid Tumor Types
BioXcel Therapeutics, Inc. (“BTI” or the “Company”) (Nasdaq: BTAI), a clinical-stage biopharmaceutical company utilizing artificial intelligence approaches to identify and advance the next wave of medicines in neuroscience and immuno-oncology,...
Dec 03, 2019 07:00 am ET
BioXcel Therapeutics Prepares to Initiate Pivotal Phase 3 Studies with BXCL501 Following Positive End-of-Phase 2 Meeting with FDA
BioXcel Therapeutics (“BTI” or “Company”) (Nasdaq: BTAI), a clinical-stage biopharmaceutical company utilizing artificial intelligence approaches to identify and advance the next wave of medicines in neuroscience and immuno-oncology, today...
Nov 26, 2019 07:00 am ET
BioXcel Therapeutics to Present at the Piper Jaffray 31st Annual Healthcare Conference
BioXcel Therapeutics, Inc. (“BTI” or the “Company”) (Nasdaq: BTAI), a clinical-stage biopharmaceutical company utilizing artificial intelligence approaches to identify and advance the next wave of medicines in neuroscience and immuno-oncology, today announced that Dr. Vimal Mehta, Founder and Chief Executive Officer of BTI, will present at the Piper Jaffray 31st Annual Healthcare Conference being held December 3 – 5, 2019 in New York City.
Nov 14, 2019 07:00 am ET
BioXcel Therapeutics Reports Third Quarter 2019 Financial Results and Provides Business Update
BioXcel Therapeutics, Inc. (“BTI” or “Company”) (Nasdaq: BTAI), a clinical-stage biopharmaceutical company utilizing artificial intelligence to identify improved therapies in neuroscience and immuno-oncology, today announced its quarterly results for the third quarter ended September 30, 2019 and provided an update on key strategic and operational initiatives.
Nov 07, 2019 07:00 am ET
BioXcel Therapeutics to Host Third Quarter 2019 Operating and Financial Results Conference Call and Webcast
BioXcel Therapeutics, Inc. (“BTI” or the “Company”) (Nasdaq: BTAI), a clinical-stage biopharmaceutical company utilizing artificial intelligence to identify improved therapies in neuroscience and immuno-oncology, today announced it will host a conference call and webcast on Thursday, November 14, 2019 at 8:30 AM Eastern Time to discuss its third quarter 2019 operating and financial results.
Oct 24, 2019 08:00 am ET
BioXcel Therapeutics to Present at the 26th Annual Prostate Cancer Foundation Scientific Retreat
BioXcel Therapeutics, Inc. (“BTI” or the “Company”) (Nasdaq: BTAI), a clinical-stage biopharmaceutical development company utilizing novel artificial intelligence approaches to identify and advance the next wave of medicines in neuroscience and immuno-oncology, today announced that BTI’s Senior Vice President and Chief Medical Officer, Vincent O’Neill, M.D., will present the first clinical results on the safety and tolerability of BXCL701, an investigational orally available innate immunity activator, in combination with a PD-1 inhibitor. Data from the first patient cohort will be presented fr
Oct 10, 2019 08:00 am ET
BioXcel Therapeutics Highlights Upcoming Major Milestones
BioXcel Therapeutics, Inc. (“BTI” or the “Company”) (Nasdaq: BTAI), a clinical-stage biopharmaceutical development company utilizing novel artificial intelligence approaches to identify and advance the next wave of medicines in neuroscience and...
Sep 26, 2019 09:11 am ET
BioXcel Therapeutics Announces Pricing of Public Offering of Common Stock
BioXcel Therapeutics, Inc. (“BTI” or the “Company”) (Nasdaq: BTAI), a clinical-stage biopharmaceutical development company, today announced the pricing of an underwritten public offering of 2,303,030 shares of common stock at a public offering...
Sep 25, 2019 04:27 pm ET
BioXcel Therapeutics Announces Proposed Public Offering of Common Stock
BioXcel Therapeutics, Inc. (“BTI” or the “Company”)  (Nasdaq: BTAI), a clinical-stage biopharmaceutical development company, today announced that it has commenced an underwritten public offering of $19.0 million of shares of its common stock. In...
Sep 18, 2019 08:00 am ET
BioXcel Therapeutics Announces BXCL501 Program Initiative for Prevention and Treatment of Acute Agitation using Wearable Digital Devices
BioXcel Therapeutics, Inc. (“BTI” or the “Company”) (Nasdaq: BTAI), a clinical-stage biopharmaceutical development company utilizing novel artificial intelligence approaches to identify and advance the next wave of medicines in neuroscience and...
Sep 04, 2019 08:00 am ET
BioXcel Therapeutics Receives FDA Orphan Drug Designation for BXCL701 for the Treatment of Acute Myeloid Leukemia (AML)
BioXcel Therapeutics, Inc. (“BTI” or the “Company”) (Nasdaq: BTAI), a clinical-stage biopharmaceutical development company utilizing novel artificial intelligence approaches to identify and advance the next wave of medicines in neuroscience and...
Aug 20, 2019 08:00 am ET
BioXcel Therapeutics Announces Award of Grant by U.S. Department of Defense’s (“DoD”) Congressionally Directed Medical Research Programs (“CDMRP”) for Development of BXCL501
BioXcel Therapeutics, Inc. (“BTI” or the “Company”) (Nasdaq: BTAI), a clinical-stage biopharmaceutical development company utilizing novel artificial intelligence approaches to identify and advance the next wave of medicines in neuroscience and...
Aug 06, 2019 07:30 am ET
BioXcel Therapeutics Reports Second Quarter 2019 Financial Results and Provides Business Update
BioXcel Therapeutics, Inc. (“BTI” or “Company”) (Nasdaq: BTAI), today announced its quarterly results for the second quarter ended June 30, 2019 and provided an update on key strategic and operational initiatives. BTI is a clinical-stage...
Jul 31, 2019 08:00 am ET
BioXcel Therapeutics to Present at the Canaccord Genuity 2019 Annual Growth Conference
BioXcel Therapeutics, Inc. (“BTI”) (Nasdaq: BTAI) today announced that Dr. Vimal Mehta, Founder and Chief Executive Officer of BTI, will present [on its product candidates] at the Canaccord Genuity 2019 Annual Growth Conference being held August 6...
Jul 30, 2019 04:01 pm ET
BioXcel Therapeutics to Report Second Quarter and Half Year 2019 Financial Results and Business Update
BioXcel Therapeutics, Inc. (“BTI”) (Nasdaq: BTAI), today announced that the Company is scheduled to release its second quarter and half year 2019 financial results on Tuesday, August 6, 2019. BTI will also hold a conference call on Tuesday, August...
Jul 22, 2019 06:00 am ET
BioXcel Therapeutics Announces BXCL501 Met Primary Endpoint in Phase 1b Placebo-Controlled Trial in the Treatment of Agitation in Patients with Schizophrenia
BioXcel Therapeutics, Inc. (“BTI”) (Nasdaq: BTAI), a clinical-stage biopharmaceutical development company utilizing novel artificial intelligence approaches to identify and advance the next wave of medicines in neuroscience and immuno-oncology,...
Jul 01, 2019 08:00 am ET
BioXcel Therapeutics Added to Russell 3000® Index
BioXcel Therapeutics, Inc. (“BTI”) (Nasdaq: BTAI) today announced that the company has been added to the broad-market Russell 3000® Index following the conclusion of the 2019 Russell indexes annual reconstitution, effective upon the opening of the...
Jun 18, 2019 08:00 am ET
BioXcel Therapeutics to Participate in the BMO 2019 Prescriptions for Success Healthcare Conference
BioXcel Therapeutics, Inc. (“BTI”) (Nasdaq: BTAI) today announced that Dr. Vimal Mehta, Founder and Chief Executive Officer of BTI, will participate in a fireside chat at the BMO 2019 Prescriptions for Success Healthcare Conference being held June...
Jun 10, 2019 08:00 am ET
BioXcel Therapeutics Completes Dosing Two Cohorts of Agitated Schizophrenia Patients with BXCL501 in a Phase 2 Efficacy Trial
BioXcel Therapeutics, Inc. (“BTI” or the “Company”) (Nasdaq: BTAI), announced today that it has completed dosing of the first two cohorts of agitated schizophrenia patients in its Phase 2 efficacy trial of BXCL501, the Company’s proprietary...
Jun 06, 2019 08:00 am ET
BioXcel Therapeutics CEO, Dr. Vimal Mehta to Participate in BIO International Convention Panel on Innovative Clinical Trial Designs
BioXcel Therapeutics, Inc. (“BTI” or “Company”) (Nasdaq: BTAI), announced today that Dr. Vimal Mehta, Chief Executive Officer and Founder of BTI, will participate in a panel at the BIO International Convention in Philadelphia, PA. BTI is a...
Jun 03, 2019 08:00 am ET
BioXcel Therapeutics Announces FDA Clearance of IND Application for Triple Combination in Pancreatic Cancer and CTA Acceptance for Double Combination in Aggressive Form of Prostate Cancer (tNEPC) for
BioXcel Therapeutics, Inc. (BTI) (Nasdaq: BTAI), today announced an update of its immuno-oncology program for BXCL701, an orally-available systemic innate-immune activator with dual mechanisms of action. BTI is a clinical-stage biopharmaceutical...
May 31, 2019 04:05 pm ET
BioXcel Therapeutics to Present at the Jefferies 2019 Global Healthcare Conference
BioXcel Therapeutics, Inc. (“BTI”) (Nasdaq: BTAI), a clinical-stage biopharmaceutical development company utilizing novel artificial intelligence approaches to identify the next wave of medicines across neuroscience and immuno-oncology, today...
May 20, 2019 07:30 am ET
BioXcel Therapeutics Achieved Targeted Exposures of BXCL501 Designed For Non-Invasive Acute Treatment of Agitation in Neuropsychiatric Diseases
BioXcel Therapeutics, Inc. (“BTI” or the “Company”) (Nasdaq: BTAI), today announced positive top line data from its Phase 1 pharmacokinetic (PK) (bioavailability) and safety study of BXCL501, a proprietary sublingual thin-film formulation of...
May 13, 2019 08:00 am ET
BioXcel Therapeutics to Highlight Advances in the BXCL501 Program at 2019 Investor Event in New York City
BioXcel Therapeutics, Inc. (“BTI”) (Nasdaq: BTAI), a clinical-stage biopharmaceutical development company utilizing novel artificial intelligence approaches to identify the next wave of medicines across neuroscience and immuno-oncology, today...
May 09, 2019 08:00 am ET
BioXcel Therapeutics to Present at the 2019 UBS Global Healthcare Conference
BioXcel Therapeutics, Inc. (“BTI”) (Nasdaq: BTAI) today announced, that Dr. Vimal Mehta, Founder and Chief Executive Officer of BTI, will present at the 2019 UBS Global Healthcare Conference, being held May 20-22, 2019 in New York, NY. BTI is a...
May 07, 2019 08:00 am ET
BioXcel Therapeutics Reports First Quarter 2019 Results and Provides Business Update
BioXcel Therapeutics, Inc. (“BTI” or “Company”) (Nasdaq: BTAI), today announced its quarterly results for the first quarter ended March 31, 2019 and provided an update on key strategic and operational initiatives. BTI is a clinical-stage...
May 02, 2019 08:36 am ET
BioXcel Therapeutics Advances Process Development for BXCL501 Thin Film Formulation
BioXcel Therapeutics, Inc. (“BTI” or “Company”) (Nasdaq: BTAI), today announced that the Company has finalized the formulation development for BXCL501 and has transitioned to automated manufacturing for its sublingual thin film containing...
Apr 29, 2019 05:17 pm ET
BioXcel Therapeutics to Host First Quarter 2019 Financial Results and Business Update
BioXcel Therapeutics, Inc. (“BTI”) (Nasdaq: BTAI), a clinical stage biopharmaceutical development company utilizing novel artificial intelligence to identify the next wave of medicines across neuroscience and immuno-oncology, today announced that...
Apr 09, 2019 09:10 am ET
Consolidated Research: 2019 Summary Expectations for Okta, Zynerba Pharmaceuticals, BioXcel Therapeutics, Capital Southwest, Amber Road, and Foundation Building Materials — Fundamental Analysis, Key P
In new independent research reports released early this morning, Capital Review released its latest key findings for all current investors, traders, and shareholders of Okta, Inc. (NASDAQ:OKTA), Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), BioXcel...
Apr 03, 2019 08:00 am ET
BioXcel Therapeutics to Present at Upcoming Investor Conferences in April
BioXcel Therapeutics, Inc. (“BTI”) (Nasdaq: BTAI) today announced, that the Company will deliver corporate overview presentations at both the H.C Wainwright & Co. Global Life Sciences Conference, April 7-9, 2019 in London, UK and the BioCentury...
Apr 01, 2019 08:03 am ET
BioXcel Therapeutics Showcases Data on BXCL701 in Combination with OX40 Agonist in Late-breaking Poster Presentation at AACR Annual Meeting
BioXcel Therapeutics, Inc. (“BTI” or the “Company”) (Nasdaq: BTAI) today presented promising preclinical data demonstrating potential for combining the Company’s BXCL701, an oral immunomodulator, and an OX40 agonist antibody as a possible...
Mar 25, 2019 08:00 am ET
BioXcel Therapeutics Files Clinical Trial Application for the Development of BXCL701 and Pembrolizumab in Neuroendocrine Prostate Cancer (tNEPC)
BioXcel Therapeutics, Inc. (“BTI”) (Nasdaq: BTAI) today announced that it has filed a Clinical Trial Application (CTA) with the U.K. health authorities for its lead immuno-oncology asset, BXCL701, an orally-available small molecule immune-modulator...
Mar 13, 2019 04:01 pm ET
BioXcel Therapeutics to Present at 29th Annual Oppenheimer Healthcare Conference
BioXcel Therapeutics, Inc. (“BTI”) (Nasdaq: BTAI) today announced, that Dr. Vimal Mehta, Founder and Chief Executive Officer of BTI, will present at the 29th Annual Oppenheimer Healthcare Conference being held March 19-20, 2019 in New York, NY. BTI...
Mar 11, 2019 08:00 am ET
BioXcel Therapeutics Announces Late Breaking Data Presentation at AACR 2019 Annual Meeting
BioXcel Therapeutics, Inc. (“BTI”) (Nasdaq: BTAI) today announced that it will present a late breaking poster featuring data from a preclinical study of the Company’s BXCL701 and an OX40-agonist antibody as a potential combination therapy for...
Mar 07, 2019 08:00 am ET
BioXcel Therapeutics Reports Fourth Quarter and Full Year 2018 Quarterly Results and Provides Business Update
BioXcel Therapeutics, Inc. (“BTI” or “Company”) (Nasdaq: BTAI), today announced quarterly results for the fourth quarter and full year ended December 31, 2018 and provided an update on key strategic and operational initiatives. BTI is a...
Mar 05, 2019 04:01 pm ET
BioXcel Therapeutics to Participate in Upcoming Investor Conferences in March
BioXcel Therapeutics, Inc. (“BTI”) (Nasdaq: BTAI) today announced, that Dr. Vimal Mehta, Founder and Chief Executive Officer of BTI, will present at the 39th Annual Cowen Healthcare Conference being held March 11-13, 2019 in Boston, Massachusetts...
Mar 04, 2019 08:00 am ET
BioXcel Therapeutics Announces Addition of Merck KGaA, Darmstadt, Germany, and Pfizer to Clinical Collaboration with Nektar for Development of Triple-combination Therapy in Pancreatic Cancer
BioXcel Therapeutics, Inc. (“BTI”) (Nasdaq: BTAI) today announced the addition of Merck KGaA, Darmstadt, Germany, which operates its biopharmaceutical business as EMD Serono in the USA and Canada, and Pfizer Inc. (NYSE: PFE) to its Nektar...
Mar 01, 2019 08:30 am ET
BioXcel Therapeutics to Host Fourth Quarter & Full Year 2018 Financial Results and Business Update Conference Call
BioXcel Therapeutics, Inc. (“BTI”) (Nasdaq: BTAI), a clinical stage biopharmaceutical development company utilizing novel artificial intelligence approaches to identify the next wave of medicines across neuroscience and immuno-oncology, today...
Feb 06, 2019 08:00 am ET
BioXcel Therapeutics to Present at 2019 BIO CEO & Investor Conference
BioXcel Therapeutics, Inc. (“BTI” or “Company”) (Nasdaq: BTAI), today announced that Dr. Vimal Mehta,  Chief Executive Officer of BTI, will present at the upcoming 2019 BIO CEO & Investor Conference being held in New York, NY on February 11-12,...
Feb 04, 2019 08:00 am ET
BioXcel Therapeutics Expands Indication for Lead Neuroscience Asset, BXCL501, to Treat Symptoms Associated with Opioid Drug Withdrawal
BioXcel Therapeutics, Inc. (“BTI” or “Company”) (Nasdaq: BTAI), today announced proof-of-concept data from its Phase 1b study of intravenously-administered dexmedetomidine (IV Dex) in patients suffering from opioid withdrawal symptoms. The positive...
Jan 09, 2019 09:50 am ET
The Most Innovative Healthcare AI Developments of 2019
HOUSTON, TX / ACCESSWIRE / January 9, 2019 / Technology has changed in the blink of an eye.
Jan 03, 2019 08:00 am ET
BioXcel Therapeutics Reports Positive Human Proof-of-Concept Data for Acute Treatment of Agitation in Patients with Alzheimer’s Disease
BioXcel Therapeutics, Inc. (“BTI”) (Nasdaq: BTAI) today announced proof-of-concept data from its Phase 1 study of IV (intravenous) dexmedetomidine (Dex) for acute treatment of agitation in patients with Senile Dementia of the Alzheimer’s Type...
Dec 27, 2018 08:00 am ET
BioXcel Therapeutics Receives FDA Fast Track Designation for BXCL501 for Acute Treatment of Agitation
BioXcel Therapeutics, Inc. (“BTI” or “Company”) (Nasdaq: BTAI), today announced that the U.S. FDA has granted Fast Track Designation for its investigational drug BXCL501, a proprietary sublingual film of dexmedetomidine, for the treatment of acute...
Dec 19, 2018 04:00 am ET
BioXcel Therapeutics Doses First Subjects in Pharmacokinetic (Bioavailability) and Safety Study of BXCL501 for the Acute Treatment of Agitation
BioXcel Therapeutics, Inc. (“BTI” or “Company”) (Nasdaq: BTAI), today announced that the first six subjects have been dosed in the Company’s Phase 1 pharmacokinetic (bioavailability) and safety study of BXCL501, a proprietary sublingual thin-film...
Dec 12, 2018 04:00 am ET
BioXcel Therapeutics Announces FDA Acceptance of IND for Lead Neuroscience Candidate, BXCL501 for the Acute Treatment of Agitation
BioXcel Therapeutics, Inc. (“BTI” or “Company”) (Nasdaq: BTAI), today announced that the U.S. Food and Drug Administration (“FDA”), has accepted its Investigational New Drug (IND) application for lead neuroscience candidate, BXCL501. BTI plans to...
Dec 03, 2018 06:00 am ET
BioXcel Therapeutics to Present at BMO Capital Markets 2018 Prescriptions for Success Healthcare Conference
BioXcel Therapeutics, Inc. (“BTI”) (Nasdaq: BTAI), a clinical stage biopharmaceutical development company utilizing novel artificial intelligence approaches to identify the next wave of medicines across neuroscience and immuno-oncology, today...
Nov 21, 2018 07:40 am ET
Market Trends Toward New Normal in Transcat, BioXcel Therapeutics, Youngevity International, Aquestive Therapeutics, TORM, and Transglobe Energy — Emerging Consolidated Expectations, Analyst Ratings
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Transcat, Inc. (NASDAQ:TRNS), BioXcel Therapeutics, Inc. (NASDAQ:BTAI),...
Nov 14, 2018 04:00 am ET
BioXcel Therapeutics Reports Positive Results from Study in Agitated Schizophrenia Patients Supporting BXCL501 Clinical Development
dosed Dexmedetomidine(Dex); no meaningful responses observed in placebo arm IV Dex well tolerated in treatment arm NEW HAVEN, Conn., Nov. 14, 2018 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (“BTI”) (Nasdaq: BTAI), a clinical stage...
Nov 09, 2018 07:00 am ET
BioXcel Therapeutics Reports Third Quarter 2018 Quarterly Results and Provides Business Update
BioXcel Therapeutics, Inc. (“BTI”) (Nasdaq: BTAI), a clinical stage biopharmaceutical development company utilizing novel artificial intelligence approaches to identify the next wave of medicines across neuroscience and immuno-oncology, today...
Nov 05, 2018 04:00 am ET
BioXcel Therapeutics Announces FDA Acceptance of IND for Lead Immuno-oncology Candidate, BXCL701, in Treatment Emergent Neuroendocrine Prostate Cancer
BioXcel Therapeutics, Inc. (“BTI” or “Company”) (Nasdaq: BTAI), today announced that the U.S. Food and Drug Administration (“FDA”), has accepted its Investigational New Drug (“IND”) application for its lead immuno-oncology candidate, BXCL701. BTI...
Nov 02, 2018 06:00 am ET
BioXcel Therapeutics to Host Third Quarter 2018 Financial Results and Business Update Conference Call
BioXcel Therapeutics, Inc. (“BTI”) (Nasdaq: BTAI), a clinical stage biopharmaceutical development company utilizing novel artificial intelligence approaches to identify the next wave of medicines across neuroscience and immuno-oncology, today...
Oct 31, 2018 04:00 am ET
BioXcel Therapeutics Announces Presentation on Functional Immunological Memory Formation Across Diverse Tumor Types at the SITC 2018 Annual Meeting
BioXcel Therapeutics, Inc. (“BTI”) (Nasdaq: BTAI), a clinical stage biopharmaceutical development company utilizing novel artificial intelligence approaches to identify the next wave of medicines across neuroscience and immuno-oncology, today...
Oct 30, 2018 04:00 am ET
BioXcel Therapeutics Provides Update on the Clinical Advancement of BXCL501 for the Acute Treatment of Agitation
BioXcel Therapeutics, Inc. (“BTI”) (Nasdaq: BTAI), a clinical stage biopharmaceutical development company utilizing novel artificial intelligence approaches to identify the next wave of medicines across neuroscience and immuno-oncology, today...
Oct 11, 2018 04:01 pm ET
BioXcel Therapeutics to Present at the 2018 BIO Investor Forum
BioXcel Therapeutics, Inc. (“BTI”) (Nasdaq: BTAI), a clinical stage biopharmaceutical development company utilizing novel artificial intelligence approaches to identify the next wave of medicines across neuroscience and immuno-oncology, announced...
Oct 08, 2018 07:00 am ET
BioXcel Therapeutics Announces Submission of IND for Lead Immuno-oncology Candidate, BXCL701, in Treatment Emergent Neuroendocrine Prostate Cancer
BioXcel Therapeutics, Inc. (“BTI”) (Nasdaq: BTAI), a clinical stage biopharmaceutical development company utilizing novel artificial intelligence approaches to identify the next wave of medicines across neuroscience and immuno-oncology, today...
Sep 24, 2018 07:00 am ET
BioXcel Therapeutics Expands Immuno-Oncology Partnership with Nektar into Clinical Development in Pancreatic Cancer
BioXcel Therapeutics, Inc. (“BTI”) (Nasdaq: BTAI), a clinical stage biopharmaceutical development company utilizing novel artificial intelligence approaches to identify the next wave of medicines across neuroscience and immuno-oncology, and Nektar...
Sep 18, 2018 08:00 am ET
BioXcel Therapeutics Enhances Leadership with Appointment of Chetan D. Lathia, Ph.D. as Senior Vice President, and Head of Translational Medicine, Clinical Pharmacology and Regulatory Affairs
BioXcel Therapeutics, Inc. (“BTI”) (Nasdaq: BTAI), a clinical stage biopharmaceutical development company utilizing novel artificial intelligence (“AI”) approaches to identify the next wave of medicines across neuroscience and immuno-oncology,...
Sep 04, 2018 08:00 am ET
BioXcel Therapeutics Appoints Dr. David C. Hanley as Vice President and Head of Global Pharmaceutical Development and Operations
BioXcel Therapeutics, Inc. (“BTI”) (Nasdaq: BTAI), a clinical stage biopharmaceutical development company utilizing novel artificial intelligence to identify the next wave of medicines across neuroscience and immuno-oncology, today announced the...
Aug 28, 2018 08:00 am ET
BioXcel Therapeutics to Present at the 20th Annual HC Wainwright Global Investment Conference
BioXcel Therapeutics, Inc. (“BTI”) (Nasdaq: BTAI), a clinical stage biopharmaceutical development company utilizing novel artificial intelligence approaches to identify the next wave of medicines across neuroscience and immuno-oncology, today...
Aug 22, 2018 08:00 am ET
BioXcel Therapeutics Establishes Immuno-Oncology Clinical Advisory Board to Advance BXCL701 Development
BioXcel Therapeutics, Inc. (“BTI”) (Nasdaq: BTAI), a clinical stage biopharmaceutical development company utilizing novel artificial intelligence approaches to identify the next wave of medicines across neuroscience and immuno-oncology, today...
Aug 08, 2018 04:01 pm ET
BioXcel Therapeutics Reports Second Quarter 2018 Financial Results and Provides Business Update
BioXcel Therapeutics, Inc. (“BTI”) (Nasdaq: BTAI), a clinical stage biopharmaceutical development company utilizing novel artificial intelligence approaches to identify the next wave of medicines across neuroscience and immuno-oncology, today...
Aug 07, 2018 07:02 am ET
BioXcel Therapeutics Strengthens Leadership Team with Industry Veteran Michael De Vivo Ph.D. as Vice President, Neuroscience
BioXcel Therapeutics, Inc. (“BTI”) (Nasdaq: BTAI), a clinical stage biopharmaceutical development company utilizing novel artificial intelligence (AI) approaches to identify the next wave of medicines across neuroscience and immuno-oncology, today...
Aug 02, 2018 04:05 pm ET
BioXcel Therapeutics to Host Second Quarter 2018 Financial Results and Business Update
BioXcel Therapeutics, Inc. (“BTI”) (Nasdaq: BTAI), a clinical stage biopharmaceutical development company utilizing novel artificial intelligence approaches to identify the next wave of medicines across neuroscience and immuno-oncology, today...
Aug 02, 2018 08:00 am ET
BioXcel Therapeutics to Present at the 38th Annual Canaccord Genuity Growth Conference
BioXcel Therapeutics, Inc. (“BTI”) (Nasdaq: BTAI), a clinical stage biopharmaceutical development company utilizing novel artificial intelligence approaches to identify the next wave of medicines across neuroscience and immuno-oncology, today...
Jul 31, 2018 08:00 am ET
BioXcel Therapeutics Enhances Leadership with Appointment of Vikas Sharma, Ph.D. as Vice President of Business Development
BioXcel Therapeutics, Inc. (“BTI”) (Nasdaq:BTAI), a clinical stage biopharmaceutical development company utilizing novel artificial intelligence approaches to identify the next wave of medicines across neuroscience and immuno-oncology, today...
Jul 24, 2018 08:00 am ET
DPP8/9 Inhibition - The Primary Mechanism of BioXcel Therapeutics’ Lead Immuno-Oncology Asset, BXCL701, Highlighted in Peer-Reviewed Journal
BioXcel Therapeutics, Inc. (“BTI”) (Nasdaq:BTAI), is a clinical stage biopharmaceutical development company utilizing proprietary artificial intelligence approaches to identify the next wave of medicines across neuroscience and immuno-oncology,...
Jul 10, 2018 08:00 am ET
BioXcel Therapeutics Forms Neuroscience Clinical Advisory Board to Support Global Development of BXCL501
BioXcel Therapeutics, Inc. (“BTI”) (Nasdaq:BTAI), a clinical stage biopharmaceutical development company utilizing novel artificial intelligence to identify the next wave of medicines across neuroscience and immuno-oncology, today announced the...
Jun 27, 2018 04:01 pm ET
BioXcel Therapeutics Reports Positive Results from Phase 1b Trial of Intravenously-dosed Dexmedetomidine Supporting BXCL501 Development
BioXcel Therapeutics, Inc. (“BTI”) (Nasdaq:BTAI), a clinical stage biopharmaceutical development company utilizing novel artificial intelligence to identify the next wave of medicines across neuroscience and immuno-oncology, today announced...
Jun 26, 2018 08:30 am ET
BioXcel Therapeutics Added to Russell Microcap® Index
BioXcel Therapeutics, Inc. (“BTI”) (Nasdaq:BTAI), a clinical stage biopharmaceutical development company utilizing novel artificial intelligence to identify the next wave of medicines across neuroscience and immuno-oncology, today announced that it...
Jun 13, 2018 08:00 am ET
BioXcel Therapeutics Appoints Dr. Cedric Burg as Vice President and Head of Global Clinical Operations and Project Management
BioXcel Therapeutics, Inc. (“BTI”) (Nasdaq:BTAI), a clinical stage biopharmaceutical development company utilizing novel artificial intelligence to identify the next wave of medicines across neuroscience and immuno-oncology, today announced the...
Jun 07, 2018 08:00 am ET
BioXcel Therapeutics Appoints Vincent J. O’Neill M.D., as Senior Vice President and Chief Medical Officer
BioXcel Therapeutics, Inc. (“BTI”) (Nasdaq:BTAI), a clinical stage biopharmaceutical development company utilizing novel artificial intelligence to identify the next wave of medicines across neuroscience and immuno-oncology, today announced the...
Jun 05, 2018 08:00 am ET
BioXcel Therapeutics to Present at the Jefferies 2018 Global Healthcare Conference
BioXcel Therapeutics, Inc. (“BTI”) (Nasdaq:BTAI), a clinical stage biopharmaceutical development company utilizing novel artificial intelligence to identify the next wave of medicines across neuroscience and immuno-oncology, today announced that...
Jun 04, 2018 08:30 am ET
BioXcel Therapeutics and Nektar Therapeutics Present Preclinical Pancreatic Cancer Data for BXCL701, NKTR-214 and Anti-PD1 Combination Therapy at ASCO 2018 Annual Meeting
BioXcel Therapeutics, Inc. (“BTI”) (Nasdaq:BTAI), a clinical stage biopharmaceutical development company utilizing novel artificial intelligence to identify the next wave of medicines across neuroscience and immuno-oncology, today announced data...
May 18, 2018 08:00 am ET
BioXcel Therapeutics to Present at 2018 UBS Global Healthcare Conference
BioXcel Therapeutics, Inc. (“BTI”) (Nasdaq:BTAI), a clinical stage biopharmaceutical development company utilizing novel artificial intelligence to identify the next wave of medicines across neuroscience and immuno-oncology, today announced that...
May 17, 2018 08:00 am ET
BioXcel Therapeutics Announces Data Presentation at ASCO 2018 Annual Meeting
BioXcel Therapeutics, Inc. (“BTI”) (Nasdaq:BTAI), a clinical stage biopharmaceutical development company utilizing novel artificial intelligence to identify the next wave of medicines across neuroscience and immuno-oncology, today announced that it...
May 14, 2018 04:01 pm ET
BioXcel Therapeutics Reports First Quarter 2018 Financial Results and Provides Business Update
BioXcel Therapeutics, Inc. (“BTI”) (Nasdaq:BTAI), a clinical stage biopharmaceutical development company utilizing novel artificial intelligence to identify the next wave of medicines across neuroscience and immuno-oncology, today announced...
Apr 26, 2018 08:30 am ET
BioXcel Therapeutics Announces Acceptance of Abstract at ASCO 2018 Annual Meeting
BRANFORD, Conn., April 26, 2018 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (“BTI”) (Nasdaq:BTAI), a clinical stage biopharmaceutical development company utilizing novel artificial intelligence to identify the next wave of medicines across neuroscience and immuno-oncology, announced today that it...
Apr 19, 2018 08:30 am ET
BioXcel Therapeutics to Ring the NASDAQ Stock Market Opening Bell on April 20, 2018
BRANFORD, Conn., April 19, 2018 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (“BTI”) (Nasdaq:BTAI), a clinical stage biopharmaceutical development company utilizing novel artificial intelligence to identify the next wave of medicines across neuroscience and immuno-oncology, today announced that the...
Mar 12, 2018 04:01 pm ET
BioXcel Therapeutics Announces Closing of Initial Public Offering
BRANFORD, Conn., March 12, 2018 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (“BTI”) (Nasdaq:BTAI), a clinical stage biopharmaceutical development company utilizing novel artificial intelligence to identify the next wave of medicines across neuroscience and immuno-oncology, today announced the closing...